Navigation Links
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview at the following investment conferences:

-- Deutsche Bank's 33rd Annual Healthcare Conference at the

InterContinental Hotel in Boston on Tuesday, May 6, 2008 at 2:10pm

Eastern Time (11:10am Pacific Time)

-- Bank of America's 2008 Healthcare Conference at the Four Seasons Hotel

in Las Vegas on Wednesday, May 14, 2008 at 4:00pm Pacific Time (7:00pm

Eastern Time)

-- JMP Securities' Seventh Annual Research Conference at the Ritz-Carlton

Hotel in San Francisco on Wednesday, May 21, 2008 at 12:00pm Pacific

Time (3:00pm Eastern Time)

Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com. To access the presentations, click on the Investor Relations tab the link entitled "Events and Presentations" on the left side of the screen. A replay of each webcast will available approximately one hour after the live webcast concludes and will remain available for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in developme
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
3. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
4. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
10. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Philadelphia, Pa. (PRWEB) September 22, 2014 ... develops rapid diagnostics for the food and beverage ... assay will be distributed under a non-exclusive agreement ... products and services. , Enartis, an Esseco Group ... BRETT to winemakers in California and other global ...
(Date:9/22/2014)... The US markets on Friday, September 19, ... Jones Industrial Average finished at 17,279.74, up 0.08% and ... S&P 500 finished the session 0.05% lower at 2,010.40. ... finished on a positive note. The S&P 500 Health ... 0.10%, with the index gaining 6.95% in the previous ...
(Date:9/21/2014)... time, scientists have discovered how to produce ultra-thin "diamond ... greater than that of today,s strongest nanotubes and polymers. ... led by John V. Badding, a professor of chemistry ... 21 September 2014 issue of the journal Nature ... our discovery is intriguing because the threads we formed ...
(Date:9/19/2014)... -- InterMune, Inc. (Nasdaq: ITMN ) today announced ... settle the litigation in the Delaware Court of Chancery ... as of August 22, 2014, among Roche Holdings, Inc., ... of the Memorandum of Understanding, the Company agreed to ... exhibit reflecting the amendment to the Company,s Schedule 14D-9 ...
Breaking Biology Technology:Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19
... 2011 Pharmaceutical organizations rely heavily on internal ... Faced with a constantly evolving communication environment, companies ... with the most appropriate tactic. It ... is the most effective approach for the many ...
... discovery of a new class of dual-acting antimalarial compounds - ... Science online, at the Science Express website ... and blood infections, attacking the Plasmodium parasite at both stages ... how scientists developed a novel assay to determine liver stage ...
... Today BioSpace , the leading life sciences employment ... Campaign , marking the 7th edition. ... highlights leading organizations across the northwestern United States and ... electronic and printed campaign map that is ...
Cached Biology Technology:Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness 2Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria 2Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria 3BioSpace Spotlights Northwest's Life Science Community 2
(Date:9/21/2014)... In recent years, new strains of bacteria have emerged ... these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, ... at least 23,000. Despite the urgent need for new ... antibiotics in the past decade. , MIT engineers have ... Using a gene-editing system that can disable any target ...
(Date:9/21/2014)... barnacles secrete very sticky proteins that help them cling ... these natural adhesives, a team of MIT engineers has ... ships or help heal wounds and surgical incisions. , ... engineered bacteria to produce a hybrid material that incorporates ... protein found in biofilms slimy layers formed by ...
(Date:9/19/2014)... Jimmy Durante of dinosaurs a newly discovered ... new dinosaur, named Rhinorex condrupus by ... Young University, lived in what is now Utah ... Cretaceous period. , Rhinorex, which translates roughly into ... relative of other Cretaceous hadrosaurs like Parasaurolophus and ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3New hadrosaur noses into spotlight 2
... The U.S. Department of Energys Office of Science ... publication, Facilities for the Future of Science: A Twenty-Year ... in deploying the scientific facilities and instruments that the ... the frontiers of science and support the Departments missions. ...
... -- Growing recognition of the importance of health as ... has prompted the Proceedings of the National Academy of ... Health to its existing section on Sustainable Development. The ... editorial by Barry R. Bloom, Dean of the Harvard ...
... has published recent findings that reveal some of the factors underlying ... The paper, Stem Cell Aging is Controlled both Intrinsically and ... issue of Cell Stem Cell. Lei Pan, Predoctoral Researcher, and Ting ... respectively. It is widely ...
Cached Biology News:DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 2DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 3DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 4DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 5Data on life expectancy show many countries clustered in high mortality traps 2Data on life expectancy show many countries clustered in high mortality traps 3Stowers Institute's Xie Lab demonstrates dual intrinsic and extrinsic control of stem cell aging 2